Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
Pediatric Blood & Cancer2007Vol. 50(3), pp. 581–587
Citations Over TimeTop 10% of 2007 papers
John M. Maris, Joshua Courtright, Peter J. Houghton, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Richard B. Lock, Mayamin Tajbakhsh, C. Patrick Reynolds, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith
Abstract
AZD2171 demonstrated broad tumor growth inhibition against the PPTP's solid tumor xenografts and much less commonly induced tumor regression. This pattern of in vivo activity, combined with the disassociation of in vitro and in vivo efficacy, are consistent with AZD2171 inhibiting growth of the PPTP's solid tumor xenografts primarily through an anti-angiogenesis mechanism of action.
Related Papers
- → Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma(2006)46 cited
- → PRMT1 is an important factor for medulloblastoma cell proliferation and survival(2022)7 cited
- → Atypical Cases of Osteosarcoma.(1991)
- THE MEDICAL IMAGING & PATHOLOGICAL ANALYSIS OF MEDULLOBLASTOMA IN CHILDREN(2006)
- → Desmoplastic medulloblastoma in an adult patient(2018)